Facebook Instagram Youtube
Speak to our experts

Stem Cell Therapy for Lupus (SLE)

At the Stem Cells Transplant Institute in Costa Rica, we offer stem cell therapy for lupus (SLE) to help reduce inflammation, support immune balance, and improve overall health through personalized regenerative treatment.

Request a consultation
Learn our protocol
Reviewed: 19 Apr 2026

What Is Lupus (SLE)?

Lupus, or systemic lupus erythematosus (SLE), is a chronic autoimmune condition in which the immune system becomes dysregulated and mistakenly targets the body’s own tissues. This abnormal immune activity leads to inflammation and can affect multiple organ systems, including the skin, joints, kidneys, lungs, heart, blood vessels, and nervous system. The disease is typically characterized by alternating periods of disease flare and remission.

Symptoms vary widely among individuals but commonly include fatigue, joint pain, skin rashes, and sensitivity to sunlight. In more severe cases, lupus may involve organ-specific complications such as kidney inflammation (lupus nephritis), cardiovascular involvement, or neurological manifestations. However, the clinical course and severity of lupus differ significantly from person to person, depending on the organs involved and the underlying immune activity.

request a free consultation

Why Seek Stem Cell Therapy for Lupus (SLE) in Costa Rica?

At the Stem Cells Transplant Institute in San José, Costa Rica, mesenchymal stem cell (MSC) therapy is offered as a complementary option to ongoing rheumatologic care, within a certified clinical facility under physician supervision.

Our treatment protocols are individualized based on the patient’s clinical status, and continuity of care is maintained in coordination with the treating rheumatologist. Our clinical team will review disease activity, organ involvement, current immunosuppressive regimen, and recent lab work before travel to determine candidacy.

Patients from the United States, Canada, and Europe frequently travel to San José to access regenerative medicine programs delivered within structured clinical environments at a fraction of the cost for equivalent treatment at home. For individuals with persistent disease activity despite standard treatment, MSC therapy may be an investigational complementary approach that may otherwise not be available to them in their home country.

Common Characteristics

  • Chronic inflammation involving one or more organ systems
  • Joint pain, swelling, and stiffness
  • Skin rashes, including photosensitive rashes
  • Fatigue and persistent low energy
  • Recurrent Fevers
  • Kidney involvement, such as lupus nephritis
  • Photosensitivity
  • Cycles of disease flare and remission
Evidence-Based Treatment

Why Stem Cell Therapy for Lupus (SLE)?

Systemic lupus erythematosus (SLE) is characterized by complex immune regulation dysregulation and persistent inflammatory activity that can affect multiple organs over time. Current research has explored various strategies aimed at modulating these immune processes.

Mesenchymal stem cells (MSCs) have been widely investigated for their immunomodulatory and anti-inflammatory properties, as well as for their potential to support tissue homeostasis and create a more favorable cellular environment in the context of chronic inflammatory diseases. 

MSC-based interventions for lupus remain experimental. Peer-reviewed studies have reported, in selected patient populations, observational improvements in certain inflammatory markers, immune-related parameters, and organ-specific indicators such as kidney involvement. However, these findings are variable and not uniformly observed across all patients. 

At SCTI, MSC-based interventions are offered as a complementary approach alongside standard care, not as a replacement for established medical treatments. 

Evidence remains preliminary, and larger, well-controlled clinical trials are still needed to clarify the magnitude, durability, and consistency of these effects.

1

Immune System Regulation

Research suggests that MSCs may influence immune activity by interacting with various immune cell populations, including T cells and B cells, and by promoting regulatory pathways associated with immune balance. These interactions are thought to contribute to a reduction in excessive immune activation observed in autoimmune conditions. (Du et al., 2022)

2

Inflammatory Modulation

MSCs have been shown to secrete anti-inflammatory signaling molecules, such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), which are involved in regulating inflammatory responses.  (Wang et al., 2021)

3

Support of Tissue Homeostasis

MSCs are known to release a range of bioactive factors that may support cellular repair processes and tissue homeostasis. In the context of chronic inflammation, these factors are hypothesized to help maintain a more favorable tissue environment in organs commonly affected by lupus. (Deng et al., 2020)

4

Microenvironment Support

Experimental studies suggest that MSCs may contribute to local microenvironmental stability by influencing vascular signaling and cellular interactions involved in tissue maintenance. These effects are thought to support overall tissue resilience in inflammatory conditions. (Du et al., 2022)

request a free consultation

Expected Benefits & Clinical Observations 

Although individual responses vary widely, published studies and clinical observations have reported potential supportive improvement in the following functional domains:

Inflammatory and immune-related laboratory markers
20-40%
Flare frequency metrics
15-35%
Patient-reported joint discomfort and fatigue
20-40%
Cutaneous manifestations
15-30%
Icono que simboliza la estrategia y el proceso cognitivo, mostrando una silueta de cabeza humana con un engranaje mecánico en su interior.
Health-related quality of life measures
20-35%
Icono morado de una cara sonriente rodeada de tres signos de más, simbolizando positividad, mejora continua y bienestar.

*These percentages summarizes ranges reported in selected clinical studies and observational cohorts under controlled conditions and standardized outcomes measures. They are not specific to any single study or to treatments performed at Stem Cells Transplant Institute. They should not be interpreted as averages, promises, or guaranteed results for individual patients. Evidence for MSC therapy for lupus erythematosus preliminary, and ongoing controlled clinical trials are still evaluating the magnitude, durability and consistency of these effects. All observations should be considered exploratory and hypothesis-generating rather than definitive proof of efficacy.

Timeline of Reported Improvements

Published studies and patient-reported outcomes suggest that improvements after mesenchymal stem cell (MSC) therapy for lupus erythematosus may develop gradually over time. These timelines are illustrative summaries rather than predictions, and individual responses vary significantly.

1-3 months
Reports of changes in patient-reported energy levels, joint-related symptoms, or flare activity in some study populations
3-6 months
Descriptions of laboratory or symptom-related parameter changes in certain cohorts; stabilization noted in some reports
6-12 months
Continued monitoring in longer-term follow-up studies, with variable patterns across patients and study designs

*These timelines summarize patterns reported across selected published studies and observational cohorts. They are not specific predictions, and they do not represent expected outcomes for any individual patient. Individual experiences vary considerably, and some patients may experience minimal or no improvement. Evidence for MSC therapy in lupus erythematosus remains preliminary, and larger controlled clinical trials are needed to validate these observations. All timelines should be interpreted as exploratory and non-confirmatory.

request a free consultation

Patient Stories & Testimonials

Frequently Asked Questions

No. MSC therapy for lupus is considered investigational and is not FDA-approved. SCTI provides treatment under Costa Rican regulations for regenerative medicine.

Yes, stem cell therapy is offered as a complement to your existing care plan. Most patients continue their medications. Decisions regarding medication use, adjustment, or discontinuation remain under the supervision of the patient’s primary treating physician or rheumatology team. We encourage close coordination with your existing healthcare providers to support safety and continuity of care.

Costs vary depending on your personalized treatment plan, including cell dosage, number of sessions, and time allowance for your visit. SCTI provides a clear, individualized cost estimate after reviewing your medical records.

In published clinical studies and observational settings, MSC-based interventions have generally been reported as well tolerated in many patients. However, individual responses can vary.

Reported short-term effects may include fatigue, mild fever, headache, or transient discomfort, though not all patients experience these effects. As with any investigational medical intervention, potential risks are not yet fully characterized, and rare or unforeseen complications cannot be completely excluded.

A comprehensive discussion of potential risks, benefits, and uncertainties is conducted during the individual medical evaluation and informed consent process prior to any intervention.

No — stem cell therapy is not a cure, and they do not eliminate the disease or guarantee the prevention of future flares. 

In research settings, MSC-based approaches have been explored for their potential immunomodulatory and anti-inflammatory properties. However, responses vary widely among individuals, and not all patients experience measurable changes. These interventions are considered investigational and are offered only as a complementary option alongside standard medical care.

Stem cell therapy for lupus (SLE) may help support immune balance and reduce inflammation. While it is not a cure, research suggests it can improve symptoms and overall quality of life.

contact an expert today

Key Research Studies

Mesenchymal Stromal Cell Therapy for Autoimmune and Rheumatic Diseases

Stem Cell Research & Therapy • 2022

Systematic review and meta-analysis evaluating safety and therapeutic efficacy of mesenchymal stromal cell transplantation in autoimmune and rheumatic disorders.

View published study

Mesenchymal Stem Cells in Animal Models of Lupus Nephritis

Stem Cell Research & Therapy • 2020

Meta-analysis demonstrating therapeutic benefits of mesenchymal stem cell therapy in experimental models of lupus nephritis.

View published study

Umbilical Cord Mesenchymal Stem Cells in Lupus

Arthritis Research & Therapy • 2014

Multicenter clinical study reporting therapeutic improvements and safety outcomes following umbilical cord MSC therapy in lupus patients.

View published study

MSC Transplantation Ameliorates Systemic Lupus Erythematosus

Stem Cell Research & Therapy • 2021

Experimental study showing MSC transplantation improved lupus disease markers through immune modulation and increased regulatory B cells.

View published study

Immunomodulatory Effects of MSC Secretome in Lupus

Bioscientia Medicina • 2025

Meta-analysis analyzing immunomodulatory mechanisms of MSC secretome therapy in systemic lupus erythematosus.

View published study

Mesenchymal Stem Cell Transplantation for Systemic Lupus Erythematosus

International Journal of Rheumatic Diseases • 2015

Clinical review discussing therapeutic potential and clinical outcomes of mesenchymal stem cell transplantation in lupus patients.

View published study

Clinical Applications of MSC Therapy in Autoimmune Diseases

Stem Cell Research & Therapy • 2022

Scientific review highlighting clinical applications, mechanisms, and therapeutic promise of MSC therapy for autoimmune conditions.

View published study
info
Location

San José, Costa Rica

Contact Us

info@stemcellstransplantinstitute.com

Call Center

+1 888 785-4170

APPLY TODAY